Novo Nordisk A/S (NVO)
NYSE: NVO · Real-Time Price · USD
54.37
-1.72 (-3.07%)
At close: Oct 17, 2025, 4:00 PM EDT
54.72
+0.35 (0.64%)
After-hours: Oct 17, 2025, 7:59 PM EDT
Novo Nordisk Revenue
Novo Nordisk had revenue of 76.86B DKK in the quarter ending June 30, 2025, with 12.93% growth. This brings the company's revenue in the last twelve months to 311.94B, up 20.90% year-over-year. In the year 2024, Novo Nordisk had annual revenue of 290.40B with 25.03% growth.
Revenue (ttm)
311.94B DKK
Revenue Growth
+20.90%
P/S Ratio
4.84
Revenue / Employee
4,032,864 DKK
Employees
77,349
Market Cap
237.72B USD
Revenue Chart
* This company reports financials in DKK.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 290.40B | 58.14B | 25.03% |
Dec 31, 2023 | 232.26B | 55.31B | 31.26% |
Dec 31, 2022 | 176.95B | 36.15B | 25.68% |
Dec 31, 2021 | 140.80B | 13.85B | 10.91% |
Dec 31, 2020 | 126.95B | 4.93B | 4.04% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 92.15B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Abbott Laboratories | 43.84B |
NVO News
- 1 day ago - FDA Approves Novo Nordisk's Rybelsus Diabetes Pill to Reduce Heart Risk - WSJ
- 1 day ago - Eli Lilly and Novo Nordisk stocks fall as Trump says he wants $150 price for GLP-1s - CNBC
- 1 day ago - Trump says Ozempic prices will be 'much lower' for Americans - Fox Business
- 2 days ago - Trump-Induced Volatility Aside, Novo Trades Cheap While Patents Protect Its Profits Until 2032 - Benzinga
- 2 days ago - Here's What Trump Said That's Pressuring Novo Nordisk and Eli Lilly Stocks - Investopedia
- 2 days ago - Novo Nordisk hires US pharma veteran as Trump pricing pressure mounts - Reuters
- 2 days ago - Eli Lilly, Novo Nordisk Stocks Drop After Trump's Ozempic Price Comment. What to Know. - Barrons
- 2 days ago - Wall Street Breakfast Podcast: Regional Bank Worries Drag Futures Lower - Seeking Alpha